- Home
- CAPS vs ATHA Comparison
CAPS vs ATHA Comparison
Compare CAPS & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPS
- ATHA
- Stock Information
- Founded
- CAPS 1987
- ATHA 2011
- Country
- CAPS United States
- ATHA United States
- Employees
- CAPS N/A
- ATHA N/A
- Industry
- CAPS
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- CAPS
- ATHA Health Care
- Exchange
- CAPS NYSE
- ATHA Nasdaq
- Market Cap
- CAPS 9.8M
- ATHA 10.6M
- IPO Year
- CAPS N/A
- ATHA 2020
- Fundamental
- Price
- CAPS $1.86
- ATHA $0.36
- Analyst Decision
- CAPS
- ATHA Buy
- Analyst Count
- CAPS 0
- ATHA 4
- Target Price
- CAPS N/A
- ATHA $11.25
- AVG Volume (30 Days)
- CAPS 1.2M
- ATHA 1.4M
- Earning Date
- CAPS 04-02-2025
- ATHA 05-09-2025
- Dividend Yield
- CAPS N/A
- ATHA N/A
- EPS Growth
- CAPS N/A
- ATHA N/A
- EPS
- CAPS N/A
- ATHA N/A
- Revenue
- CAPS $43,416,000.00
- ATHA N/A
- Revenue This Year
- CAPS $7.87
- ATHA N/A
- Revenue Next Year
- CAPS N/A
- ATHA N/A
- P/E Ratio
- CAPS N/A
- ATHA N/A
- Revenue Growth
- CAPS N/A
- ATHA N/A
- 52 Week Low
- CAPS $1.58
- ATHA $0.22
- 52 Week High
- CAPS $16.18
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- CAPS N/A
- ATHA 68.44
- Support Level
- CAPS N/A
- ATHA $0.27
- Resistance Level
- CAPS N/A
- ATHA $0.33
- Average True Range (ATR)
- CAPS 0.00
- ATHA 0.03
- MACD
- CAPS 0.00
- ATHA 0.01
- Stochastic Oscillator
- CAPS 0.00
- ATHA 91.60
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.